Company news · 2025-11-24
Innovative immunotherapy pathway: building an mRNA-DC–mediated neoantigen NRT response platform
Runsheng Cell reports AI neoantigen prediction, patent cluster, completed preclinical work, and pilot-scale process toward IND-oriented development.
Toward IND-oriented development
Guangzhou Runsheng Cytomed Technology Co., Ltd. announced progress for its neoantigen-vaccine-centred individualized precision immunotherapy program: an in-house AI neoantigen prediction system paired with a patent cluster has completed preclinical milestones and entered pilot-scale process translation—a step the company frames as moving toward industrialized immuno-oncology R&D.
Technology stack: AI + patents (as cited)
The pipeline combines neoantigen vaccines with neoantigen-reactive T cells. Patent numbers referenced in the release include:
- mRNA vector construction (ZL 2024 1 0094352.1)
- Cryopreserved mature DC methods (ZL 2024 1 1621043.1)
- Tumor-specific antigen peptide libraries (ZL 2025 1 0289793.1)
- MC38 colorectal cancer combination composition (ZL 2025 1 0289586.6)
The AI platform integrates genomics, immune repertoire, and clinical datasets; the company cites >60% prediction accuracy in internal materials—interpret with caution pending peer review.
Manufacturing and regulatory path
The update notes animal efficacy studies, pilot process scale-up, and IND preparation with tertiary hospital collaborators in China.
Patent scope is defined by claims; clinical utility requires regulatory review and controlled trials. Informational content only.